learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Advancements in Treatment Strategies for Androgenetic Alopecia: Novel Therapies and Future Perspectives
New treatments for androgenetic alopecia show promise but need more research for validation.
research Medical Physics and Laser Technology: Advancements and Applications in Modern Healthcare
Advancements in medical physics and laser technology are improving healthcare but access remains unequal globally.
research Harnessing Microbiome, Bacterial Extracellular Vesicle, and Artificial Intelligence for Polycystic Ovary Syndrome Diagnosis and Management
Microbiome analysis, BEVs, and AI can improve PCOS diagnosis and treatment.
research Artificial Intelligence in Aesthetic Medicine: Applications, Challenges, and Future Directions
AI improves aesthetic medicine but faces challenges like biases and privacy issues that need addressing for successful integration.
research Hydrogel Composites for Multifunctional Biomedical Applications
Hydrogel composites have great potential in regenerative medicine, tissue engineering, and drug delivery.
Community Join
5 / 434 resultscommunity A Logical, Step-by-Step Guide to Managing Androgenetic Alopecia (No BS)
Finasteride and minoxidil are recommended as first-line treatments for hair loss, with dutasteride and oral minoxidil as stronger options if needed. Hair transplants should only be considered after achieving stability with medication, and non-surgical options are suggested if medications are ineffective.
community Finally, some real breakthroughs. A comparison of the two leading baldness treatments: PP405 versus ABS-201
PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.
community How many years can we expect PP405 to be on the market
PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.
community How do we only have two treatments to combat hair loss at this point in time?
The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.
community AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.